Company Encyclopedia
View More
name
Sinopep
688076.SH
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was founded in 2009 and is headquartered in Hangzhou, China.
3.049 T
688076.SHMarket value -Rank by Market Cap -/-

Financial Score

18/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking26/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE17.42%A
    • Profit Margin26.25%A
    • Gross Margin73.01%A
  • Growth ScoreB
    • Revenue YoY20.52%B
    • Net Profit YoY18.32%B
    • Total Assets YoY50.59%A
    • Net Assets YoY18.77%A
  • Cash ScoreB
    • Cash Flow Margin380.95%C
    • OCF YoY20.52%B
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreC
    • Gearing Ratio53.15%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ST Sinopep: Agomelatine tablets are expected to be selected for the 11th batch of national centralized drug procurement

    ST Sinopep announced that the company participated in the bidding organized by the National Organization for Drug Procurement Office for the 11th batch of national centralized drug procurement, and the company's product Agomelatine tablets is expected to be selected in this centralized procurement

    Zhitong·
    SH
    688076
    -0.44%
    Zhitong·
    SH
    688076
    -0.44%

    Sinopep released its performance for the first three quarters, with a net profit attributable to the parent company of 445 million yuan, an increase of 26.92%

    According to the Zhitong Finance APP, ST Sinopep released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.527 billion yuan, a year-on-year increase of 21.95%. The net profit attributable to shareholders of the listed company was 445 million yuan, a year-on-year increase of 26.92%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 437 million yuan, a year-on-year increase of 23.20%. The basic earnings per share were 1.42 yuan

    Zhitong·
    SH
    688076
    -0.44%
    Zhitong·
    SH
    688076
    -0.44%

    Sinopep expects a profit increase, with an estimated net profit attributable to shareholders of 130 million to 140 million yuan in the third quarter, an increase of 5.62% to 13.74% year-on-year

    According to the Zhitong Finance APP, ST Sinopep released its third-quarter performance forecast, expecting a net profit attributable to the parent company's owners of 130 million to 140 million yuan in the third quarter of 2025, an increase of 5.62% to 13.74% year-on-year. During the reporting period, the company implemented the business philosophy of "time leading, technology leading," and various main businesses were carried out in an orderly manner, achieving steady growth in net profit

    Zhitong·
    SH
    688076
    -0.44%
    Zhitong·
    SH
    688076
    -0.44%

    FOCUS-Chinese companies turn to generics as shipments behind US weight-loss craze fade

    Chinese companies are shifting focus to producing generic versions of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound as U.S. shipments decline due to regulatory restrictions. Eight Chinese firms, including Jiangsu Sinopep and Hybio Pharmaceutical, previously supplied raw ingredients for over a billion doses sold online. With patents expiring, these companies aim to launch their own generics, although manufacturing complexities may hinder explosive growth. The market for compounded drugs has diminished, leading to a significant drop in shipments of semaglutide and tirzepatide ingredients.

    Reuters·
    US
    LLY
    +2.05%
    US
    NVO
    -0.13%
    Reuters·
    US
    LLY
    +2.05%
    US
    NVO
    -0.13%

    Sinopep released its half-year performance, with a net profit attributable to the parent company of 310 million yuan, an increase of 36.49%

    ST Sinopep released its 2025 semi-annual report, with operating revenue of 1.048 billion yuan, a year-on-year increase of 26.07%; net profit attributable to shareholders was 310 million yuan, a year-on-year increase of 36.49%. The net profit after deducting non-recurring gains and losses was 306 million yuan, a year-on-year increase of 33.49%. Basic earnings per share were 0.99 yuan, mainly benefiting from the growth in sales revenue of peptide raw materials

    Zhitong·
    SH
    688076
    -0.44%
    Zhitong·
    SH
    688076
    -0.44%
    © 2025 Longbridge｜Disclaimer